{"entity":{"id":"idea-fund-mcbs-linked-pricing","kind":"idea","name":"Launch prices indexed to the ESMO benefit scale, revisited when survival matures","aka":[],"tldr":"Pay more for drugs that clearly help people live longer or better, and less for those that barely move the needle, using a public benefit scale doctors already use.","summary":"National payers adopt a rule that reimbursed price at launch is tied to the ESMO Magnitude of Clinical Benefit Scale (or ASCO Value Framework) grade of the pivotal evidence, with a mandatory renegotiation when overall survival or quality-of-life data mature. Grade 4 to 5 (or A to B in curative settings) commands a premium band; grade 1 to 2 is reimbursed only at or near the price of the comparator. Several European payers already consult the scale informally; making the link explicit and automatic changes the return calculus for marginal drugs before they enter development.","asOf":"2026-09-08","links":[{"label":"ESMO Magnitude of Clinical Benefit Scale","url":"https://www.esmo.org/guidelines/esmo-mcbs"}],"tags":[],"related":["idea-fund-value-based-patent-extension","idea-fund-pay-for-cure-annuities"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esmo","asco"],"pathways":[],"terms":["os","pfs"],"trials":[],"people":[],"bottlenecks":["b-incentive-misalignment","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Explicit MCBS-indexed pricing across a group of countries lowers the average launch price of low-benefit oncology drugs by at least 30% and, within eight years, increases the proportion of pivotal trials designed to achieve high MCBS grades (overall survival, quality of life endpoints).","rationale":"Value-based frameworks exist and are validated but have no teeth; where price is linked to benefit (Germany's AMNOG added-benefit assessment, France's ASMR rating) evidence of a shift in development priorities has been reported. Oncology has the best-developed benefit scales of any specialty.","test":"A payer coalition applies the rule to all new oncology reimbursements for three years and compares launch prices and pivotal trial designs of subsequent filings with a control set of countries.","maturity":"speculative","actor":"payer","cost":"small","horizonYears":3},"route":"/ideas/idea-fund-mcbs-linked-pricing/","neighbours":{"idea":[{"id":"idea-fund-pay-for-cure-annuities","kind":"idea","name":"Outcome-based annuity payments for potentially curative one-time therapies","route":"/ideas/idea-fund-pay-for-cure-annuities/"},{"id":"idea-fund-value-based-patent-extension","kind":"idea","name":"Patent term extension scaled to proven survival gain","route":"/ideas/idea-fund-value-based-patent-extension/"}],"institution":[{"id":"asco","kind":"institution","name":"American Society of Clinical Oncology (ASCO)","route":"/institutions/asco/"},{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/"}],"term":[{"id":"os","kind":"term","name":"Overall survival (OS)","route":"/terms/os/"},{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}]}}